Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and a⦠read more
Healthcare
Biotechnology
43 years
USD
Exclusive to Premium users
$6.07
Price-2.73%
-$0.17
$93.005m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$52.812m
-
1y CAGR-
3y CAGR-
5y CAGR-$19.020m
-
1y CAGR-
3y CAGR-
5y CAGR-$301,506.03
-
1y CAGR-
3y CAGR-
5y CAGR$88.600m
$109.338m
Assets$20.738m
Liabilities$2.860m
Debt2.6%
-
Debt to EBITDA-$7.051m
-
1y CAGR-
3y CAGR-
5y CAGR